论文部分内容阅读
首次心肌梗塞后存活的病人,发病后6～7个月期间危险性很大,在此期间,死亡率可高达16%,其中60～80%是由于心脏性猝死。最近,安妥兰(Anturan)再梗塞试验(ART)研究组报道,血小板抑制剂亚硫吡拉宗(Sulfinpyrazone,又译磺吡唑酮)在急性心肌梗塞后的高危险期中可明显降低心脏性猝死的发生率,该药具有抗血栓或抗血小板聚集,增加侧支血流,缩小心肌损害的范围及预防细胞电解质不平衡的作用。此外,亦有提出该药可减少
Patients who survive after their first myocardial infarction are at very high risk of developing 6-7 months after onset, with a mortality rate of up to 16% during this period, of which 60-80% are due to sudden cardiac death. Recently, the Anturan Re-Infarction Study (ART) team reported that the platelet inhibitor, sulfinpyrazone, significantly reduces sudden cardiac death in high-risk patients after acute myocardial infarction The drug has antithrombotic or anti-platelet aggregation, increased collateral blood flow, reduce the scope of myocardial damage and prevent cell electrolyte imbalance. In addition, it has also been suggested that the drug may be reduced